TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation-Reference-Cited by-同舟云学术

TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation

Published:2020-04 Issue:4 Volume:31 Page:726-740.e8
ISSN:1550-4131
Container-title:Cell Metabolism
language:en
Short-container-title:Cell Metabolism

Author:

Liu Dan,Zhang Peng,Zhou Junjie,Liao Rufang,Che Yan,Gao Mao-Mao,Sun Jiaqi,Cai Jingjing,Cheng Xu,Huang Yongping,Chen Guopeng,Nie Hongyu,Ji Yan-Xiao,Zhang Xiao-Jing,Huang Zan,Xu Haibo,She Zhi-Gang,Li Hongliang

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Physiology

Reference37 articles.

1. Innate immune regulatory networks in hepatic lipid metabolism;Bai;J. Mol. Med. (Berl.),2019

2. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses;Boone;Nat. Immunol.,2004

3. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease;Cai;Trends Endocrinol. Metab.,2018

4. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease;Cai;Med. Res. Rev.,2019

5. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment;Chen;Gene Expr.,2019

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Activation of AMPK Prevents Drp1-mediated Mitochondrial Fission and Alleviates Hepatic Steatosis In vitro;Current Molecular Medicine;2024-12

2. Overexpression of DUSP26 gene suppressed the proliferation, migration, and invasion of human prostate cancer cells;Experimental Cell Research;2024-10

3. The Role of Tripartite Motif Family Proteins in Chronic Liver Diseases: Molecular Mechanisms and Therapeutic Potential;Biomolecules;2024-08-21

4. Adenosine kinase protects against acetaminophen-induced acute liver injury by activating autophagy in hepatocytes;Cell Biology and Toxicology;2024-07-27

5. USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1;Journal of Translational Medicine;2024-07-20